基于非增强CT与临床因素的简易指数用于预测非酒精性脂肪性肝病的开发与验证
本研究回顾性纳入2218例活体肝移植供者,均有肝活检及3天内CT,按2:1随机分为开发队列与测试队列。基于非增强CT的肝脾衰减差(CTL-S)、体质量指数、天冬氨酸转氨酶及甘油三酯构建临床-CT指数,在测试队列中其AUC为0.81,优于CTL-S(0.74)及临床指数(0.73-0.75)。作者认为该指数诊断非酒精性脂肪性肝病比单独CTL-S或临床指数更准确,可能有助于临床筛查。
要点
- 临床-CT指数由非增强CT的肝脾衰减差(CTL-S)、体质量指数、天冬氨酸转氨酶及甘油三酯构成,在测试队列诊断非酒精性脂肪性肝病的AUC为0.81。
- 测试队列中临床-CT指数的AUC(0.81)优于CTL-S(0.74)及临床指数(0.73-0.75),差异均有统计学意义(P<0.001)。
- 开发队列确定的切点中,≥46时敏感度89%、特异度41%;≥56.5时敏感度57%、特异度89%,并在测试队列评估诊断性能。
核心结论
- 临床-CT指数诊断非酒精性脂肪性肝病比单独CTL-S或临床指数更准确,可能有助于临床筛查非酒精性脂肪性肝病。
研究设计与样本
- 回顾性研究纳入2218例活体肝移植供者,均有肝活检及3天内CT,按2:1随机分为开发队列与测试队列。
- CTL-S通过非增强CT上肝衰减减去脾衰减计算。
- 对开发队列行多变量逻辑回归分析,构建预测病理证实的非酒精性脂肪性肝病的临床-CT指数。
- 诊断性能通过分析受试者工作特征曲线下面积(AUC)评估。
- 临床-CT指数的切点在开发队列按90%敏感度和90%特异度确定,并在测试队列评估其诊断性能。
关键影像表现/征象
- CTL-S为肝衰减与脾衰减的差值,在非增强CT上测量。
诊断标准与关键数值
- 临床-CT指数包含CTL-S、体质量指数、天冬氨酸转氨酶及甘油三酯浓度。
- 测试队列中临床-CT指数诊断非酒精性脂肪性肝病的AUC为0.81,CTL-S为0.74(P<0.001),临床指数为0.73-0.75(P<0.001)。
- 切点≥46时敏感度89%、特异度41%;切点≥56.5时敏感度57%、特异度89%。
临床应用与阅片要点
- 临床-CT指数可能有助于临床筛查非酒精性脂肪性肝病,作者认为其比单独CTL-S或临床指数更准确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: A widely applicable, non-invasive screening method for non-alcoholic fatty liver disease (NAFLD) is needed. We aimed to develop and validate an index combining computed tomography (CT) and routine clinical data for screening for NAFLD in a large cohort of adults with pathologically proven NAFLD.
MATERIALS AND METHODS: This retrospective study included 2218 living liver donors who had undergone liver biopsy and CT within a span of 3 days. Donors were randomized 2:1 into development and test cohorts. CTL-S was measured by subtracting splenic attenuation from hepatic attenuation on non-enhanced CT. Multivariable logistic regression analysis of the development cohort was utilized to develop a clinical-CT index predicting pathologically proven NAFLD. The diagnostic performance was evaluated by analyzing the areas under the receiver operating characteristic curve (AUC). The cutoffs for the clinical-CT index were determined for 90% sensitivity and 90% specificity in the development cohort, and their diagnostic performance was evaluated in the test cohort.
RESULTS: The clinical-CT index included CTL-S, body mass index, and aspartate transaminase and triglyceride concentrations. In the test cohort, the clinical-CT index (AUC, 0.81) outperformed CTL-S (0.74; p < 0.001) and clinical indices (0.73-0.75; p < 0.001) in diagnosing NAFLD. A cutoff of ≥ 46 had a sensitivity of 89% and a specificity of 41%, whereas a cutoff of ≥ 56.5 had a sensitivity of 57% and a specificity of 89%.
CONCLUSION: The clinical-CT index is more accurate than CTL-S and clinical indices alone for the diagnosis of NAFLD and may be clinically useful in screening for NAFLD.
引用
- Ahn Y, Yun SC, Lee SS, et al. Development and Validation of a Simple Index Based on Non-Enhanced CT and Clinical Factors for Prediction of Non-Alcoholic Fatty Liver Disease. Korean J Radiol. 2020. PMID: 32193889. doi:10.3348/kjr.2019.0703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。